Abstract
Omalizumab is recently developed monoclonal anti-IgE antibody. Clinical trials have demonstrated its efficacy in patients with moderate-to-severe and severe or poorly controlled allergic asthma, in patients with seasonal and perennial allergic disease and in subjects with concomitant asthma and allergic rhinitis. Patients with more severe asthma appear to obtain the greatest benefit from omalizumab therapy. Omalizumab is well tolerated and has a good safety profile. Anti-inflammatory activity has been shown in both allergic asthma and allergic rhinitis [1,2]. Omalizumab is not a firstline therapy in asthmatic patients. FDA (Food and Drug Administration ) approved omalizumab use in June of 2003 for patients satisfying the following criteria (all must be present): 1- total IgE concentration in serum 30-700 klU L. 2- skin test positive for at least one perennial allergen; 3- specific IgE concentration positive for at least one perennial allergen (house dust mite, cat and dog); 4- asthma: moderate to severe persistent asthma; 5- age: > 12 years; 6- inadequate control despite inhaled corticosteroids
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Anti-Immunoglobulin E Treatment with Omalizumab in Allergic Diseases an Update on Anti-Inflammatory Activity and Clinical Efficacy
Volume: 7 Issue: 1
Author(s): I. Olcay
Affiliation:
Abstract: Omalizumab is recently developed monoclonal anti-IgE antibody. Clinical trials have demonstrated its efficacy in patients with moderate-to-severe and severe or poorly controlled allergic asthma, in patients with seasonal and perennial allergic disease and in subjects with concomitant asthma and allergic rhinitis. Patients with more severe asthma appear to obtain the greatest benefit from omalizumab therapy. Omalizumab is well tolerated and has a good safety profile. Anti-inflammatory activity has been shown in both allergic asthma and allergic rhinitis [1,2]. Omalizumab is not a firstline therapy in asthmatic patients. FDA (Food and Drug Administration ) approved omalizumab use in June of 2003 for patients satisfying the following criteria (all must be present): 1- total IgE concentration in serum 30-700 klU L. 2- skin test positive for at least one perennial allergen; 3- specific IgE concentration positive for at least one perennial allergen (house dust mite, cat and dog); 4- asthma: moderate to severe persistent asthma; 5- age: > 12 years; 6- inadequate control despite inhaled corticosteroids
Export Options
About this article
Cite this article as:
Olcay I., Anti-Immunoglobulin E Treatment with Omalizumab in Allergic Diseases an Update on Anti-Inflammatory Activity and Clinical Efficacy, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2008; 7 (1) . https://dx.doi.org/10.2174/187152308783769131
DOI https://dx.doi.org/10.2174/187152308783769131 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting NPY, CRF/UCNs and NPS Neuropeptide Systems to Treat Alcohol Use Disorder (AUD)
Current Medicinal Chemistry Ventilation Therapy for Patients Suffering from Obstructive Lung Diseases
Recent Patents on Inflammation & Allergy Drug Discovery Receptor Dimerization - Rationale for the Design of Bivalent Ligands
Current Topics in Medicinal Chemistry Direct Targets and Subsequent Pathways for Molecular Hydrogen to Exert Multiple Functions: Focusing on Interventions in Radical Reactions
Current Pharmaceutical Design Treatment Options for Cystic Fibrosis: State of the Art and Future Perspectives
Reviews on Recent Clinical Trials ADAMs and Ectododomain Proteolytic Shedding in Leucocyte Migration: Focus on L-Selectin and ADAM17
Current Immunology Reviews (Discontinued) Breaking the Skin Barrier: Achievements and Future Directions
Current Pharmaceutical Design Dipeptidyl Peptidase-4 Inhibitor Induced Angioedema – An Overlooked Adverse Drug Reaction?
Current Diabetes Reviews Antioxidant Food Supplements and Obesity-Related Inflammation
Current Medicinal Chemistry Monoclonal Antibodies and their Target Specificity Against SARS-CoV-2 Infections: Perspectives and Challenges
Recent Patents on Biotechnology Gut Microbiota and Alcoholic Liver Disease
Reviews on Recent Clinical Trials <i>Nigella sativa</i> – A Functional Spice From A Pharaoh’s Tomb to Modern Healthcare
The Natural Products Journal Knowledge, Attitude, and Behavior in Avoiding Environmental Tobacco Smoke Exposure at Home among Pregnant Women
Current Women`s Health Reviews A High Accumulation of Hair Minerals in Mongolian People: 2nd Report; Influence of Manganese, Iron, Lead, Cadmium and Aluminum to Oxidative Stress, Parkinsonism and Arthritis
Current Aging Science Nasal <i>In-situ</i> Gel: An Approach to Enhance Therapeutic Benefits of the Drug
Drug Delivery Letters Patent Annotations
Recent Patents on Inflammation & Allergy Drug Discovery Treatment with Paracetamol is not Associated with Increased Airway Sensitivity and Risk of Asthma in Rats
Current Drug Safety Quantitative Structure Activity Relationship and Design of Phenyl Alkyl Ketone Derivatives as Inhibitors of Phosphodiesterase 4
Current Enzyme Inhibition Role of Genetic Interactions in Lung Diseases Detection Using Computational Approaches: A Review
Current Chinese Computer Science Acute Respiratory Failure in Obstetric Patients
Current Women`s Health Reviews